Eli Lilly to Buy Pre-Clinical Biotech CrossBridge for Up to $300 Million
By Colin Kellaher
Eli Lilly has agreed to pay up to $300 million for pre-clinical biotechnology company CrossBridge Bio in a deal that bolsters the drugmaker's cancer pipeline.
The purchase price includes an undisclosed upfront payment, along with a potential milestone payment, CrossBridge said Tuesday.
Houston-based CrossBridge is developing dual-payload antibody-drug conjugates, or ADCs, with its lead candidate expected to enter clinical studies later this year.
ADCs work like guided missiles by pairing antibodies with toxic agents and helping deliver chemotherapy directly to tumors.
Eli Lilly in January won U.S. Food and Drug Administration breakthrough-therapy designation for its sofetabart mipitecan ADC drug candidate for certain patients with ovarian cancer.
The Indianapolis company last year announced plans to build a $5 billion manufacturing plant in Virginia where it will increase its domestic production of ADCs.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 14, 2026 10:52 ET (14:52 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
5 Stocks to Buy Trading at Big Discounts
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States